Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses

• Published in: The American journal of drug and alcohol abuse Vol. 46; no. 5; pp. 565 - 576
• Main Authors: Lim, Aaron C., Grodin, Erica N., Green, Rejoyce, Venegas, Alexandra, Meredith, Lindsay R., Courtney, Kelly E., Moallem, Nathasha R., Sayegh, Philip, London, Edythe D., Ray, Lara A.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02-09-2020; Taylor & Francis Ltd
• Subjects: Adult; Amphetamine-Related Disorders - drug therapy; Central Nervous System Stimulants - pharmacology; Cognition - drug effects; Cognitive functioning; Craving; Craving - drug effects; Cross-Over Studies; Double-Blind Method; Double-blind studies; Drug abuse; Drugs; Executive Function; Female; Functional connectivity; Humans; Los Angeles; Male; Methamphetamine; Methamphetamine - pharmacology; Naltrexone; Naltrexone - therapeutic use; Narcotic Antagonists - therapeutic use; Narcotics; Neuropsychological assessment; Opioids; Predictions; Premorbid; Responses; Stimulants; Substance abuse; substance use disorder; Young Adult; Los Angeles; craving; substance use disorder; naltrexone; Methamphetamine; executive function
• ISSN: 0095-2990; 1097-9891
• DOI: 10.1080/00952990.2020.1741002

Background: Emerging evidence suggests that opioid receptor antagonists, such as naltrexone, are effective pharmacotherapies for alcohol, opioid, and possibly stimulant use disorders. It is posited that naltrexone exerts its effects, in part, by increasing functional connectivity between neural reward circuitry and frontal systems implicated in executive function. Yet no studies had examined whether executive function moderates these effects.
Objectives: This study examined whether a composite measure of executive function (EF) moderates the effect of naltrexone on craving for methamphetamine and subjective responses following infusion of the drug.
Methods: Individuals with methamphetamine use disorder (N = 30; 27% female) completed baseline neurocognitive assessments of premorbid and executive function, and an executive function factor was computed. Participants then underwent a randomized, double-blind, cross-over study of titration with naltrexone and placebo. Participants then received a 30-mg intravenous methamphetamine infusion and completed subjective response questionnaires at 8 times in the 120 minutes post-infusion.
Results: Multilevel mixed models indicated a significant EF × medication interaction, reflecting greater effects of naltrexone to decrease "desire to access the drug", "want more of the drug", "crave the drug", "feel drug effects" and "feel high" in participants with low EF compared to those with high EF (Bs = .36-1.29, SEs = .14-.17, ps<0.01). These effects remained significant after controlling for premorbid cognitive functioning, baseline responses to methamphetamine, severity of methamphetamine use, and methamphetamine-related functional problems.
Conclusion: Naltrexone may be especially effective in methamphetamine-dependent individuals with low EF. Neuropsychological assessments may also provide predictive clinical utility not captured by traditional measures of substance use severity.